brand names of glp 1 agonists List approved and pending GLP-1 medications GLP-1 Costs Explained: Managing Coverage
Description
Semaglutide was approved in 2017 as Ozempic for diabetes, and in 2021 as Wegovy for obesity
Innovations in drug delivery methods and sustained R&D investments further enhance market potential
Understanding their distinct mechanisms, clinical evidence bases, and how genetic and biomarker data inform personalized treatment selection helps patients and providers make evidence-based decisions
This acquisition is aimed at enhancing its portfolio with the addition of Metsera's Next-Generation Obesity Portfolio.
